Point-of-care testing is the fastest-growing site-of-testing segment in IVD globally — expected to grow at a CAGR approximately double that of central laboratory testing through 2030. The COVID-19 pandemic permanently shifted patient and clinician expectations toward faster, more convenient diagnostic results — and the IVD industry is responding with a new generation of connected, miniaturized, and multiplex POC platforms. Abbott's i-STAT and ID NOW, Roche's cobas Liat, bioMérieux's BIOFIRE FILMARRAY, and Siemens' point-of-care portfolio are competing across emergency departments, physician offices, urgent care centers, and increasingly the home. The regulatory pathway for home-use IVD — FDA OTC clearance and the EU IVDR self-test classification — has become more navigable as the COVID-19 home test market demonstrated consumer readiness at scale.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• POC and Decentralized Testing Market Size and Forecast 2025-2030 by Segment and Region
• Emergency Department POC — Critical Care, Cardiac, and Rapid Infectious Disease Testing
• Physician Office and Urgent Care — Respiratory, Strep, Flu, and Metabolic Testing
• Home Testing — COVID-19, Pregnancy, STI, and Chronic Disease Monitoring
• Connected POC Platforms — Bluetooth, Cloud Connectivity, and EHR Integration
• Multiplex POC Testing — Syndromic Panels at the Point of Care
• CLIA Waiver Strategy — Regulatory Path for POC Test Deployment in the U.S.
• Competitive Landscape — Abbott, Roche, bioMérieux, Siemens, BD, and New Entrants
• Regional Analysis — POC Adoption and Decentralization Trends Across 92 Countries
• Investment and Partnership Opportunities — Platform Technology and Channel Access